Hunan Xiangzhong Pharmaceutical Co., Ltd.

Primary Objective: In accordance with relevant bioequivalence testing regulations, we selected Piropirone Hydrochloride Tablets (trade name: Lullan®; strength: 8mg), certified by Sumitomo Fama Co., Ltd., as the reference formulation. We conducted a human bioequivalence study on the test formulation, Piropirone Hydrochloride Tablets (strength: 8mg), manufactured and supplied by CR Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd., under fasting and postprandial administration conditions. We compared the absorption rate and extent of absorption of the drug in the test formulation with those in the reference formulation to determine if the differences were within acceptable ranges, and evaluated the bioequivalence of the two formulations under fasting and postprandial administration conditions. Secondary Objective: To observe the safety of oral administration of the test formulation, Piropirone Hydrochloride Tablets (strength: 8mg), and the reference formulation, Piropirone Hydrochloride Tablets (trade name: Lullan®; strength: 8mg), in healthy participants.

Primary objective: To compare the differences in the extent and rate of absorption of lithium carbonate tablets (specification: 0.25 g) provided by Hunan Xiangzhong Pharmaceutical Co., Ltd. and lithium carbonate tablets (trade name: TERALITHE®; specification: 0.25 g) approved by LABORATOIRES DELBERT in healthy Chinese population under fasting and fed conditions. Secondary objective: To evaluate the safety of lithium carbonate tablets (specification: 0.25 g) provided by Hunan Xiangzhong Pharmaceutical Co., Ltd. and lithium carbonate tablets (trade name: TERALITHE®; specification: 0.25 g) approved by LABORATOIRES DELBERT in healthy Chinese population under fasting and fed conditions.

Main research purpose: According to the regulations on bioequivalence testing, select Bripipiprazole Tablets (trade name: REXULTI®, specification: 2 mg) of Otsuka Manufacturing Co., Ltd. as the licensee as the reference preparation. The test preparation Bripiprazole tablets (specification: 2 mg) provided by Xiangzhong Pharmaceutical Co., Ltd. were subjected to fasting and postprandial administration human bioequivalence tests to compare the absorption speed and extent of the drug in the test preparation with the reference preparation. Whether the difference is within the acceptable range, the bioequivalence of the two formulations under fasting and postprandial administration conditions was evaluated. Secondary research purpose: To observe the safety of the test preparation Bripipiprazole Tablets (specification: 2 mg) and the reference preparation Bripipiprazole Tablets (trade name: REXULTI®, specification: 2 mg) orally administered to healthy volunteer subjects.